Cargando…
Detection of the anti-p53 antibody response in malignant and benign pancreatic disease.
Genomic alterations in the p53 tumour-suppressor gene and overexpression of p53 protein, resulting from gene mutations, are frequently found in pancreatic cancer. In this study we analysed the sera of 160 patients with malignant and benign pancreatic diseases for the presence of circulating antibodi...
Autores principales: | Marxsen, J., Schmiegel, W., Röder, C., Harder, R., Juhl, H., Henne-Bruns, D., Kremer, B., Kalthoff, H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033558/ https://www.ncbi.nlm.nih.gov/pubmed/7947080 |
Ejemplares similares
-
Overexpression of p53 protein during pancreatitis.
por: Maacke, H., et al.
Publicado: (1997) -
Immunohistochemical analysis of p53 protein expression in benign and malignant skin tumors using a panel of anti-p53 antibodies.
por: Ro, Y. S., et al.
Publicado: (1993) -
Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
por: Graeven, U, et al.
Publicado: (2006) -
Autocrine Stimulation of Human Pancreatic Duct–Like Development by Soluble Isoforms of Epimorphin in Vitro
por: Lehnert, Lasse, et al.
Publicado: (2001) -
Management of Benign and Malignant Pancreatic Duct Strictures
por: Dawod, Enad, et al.
Publicado: (2018)